Eltrombopag ethanolamine tablets instruction manual brief introduction

Eltrombopag Olamine Tablets (Eltrombopag Olamine Tablets) is an oral small-molecule thrombopoietic agent that belongs to the thrombopoietin receptor agonist class of drugs. It is mainly used to treat thrombocytopenia caused by immune or other diseases. This drug was originally developed by Novartis and has been approved by many countries for the treatment of chronic immune thrombocytopenia (ITP), hepatitis C-related thrombocytopenia, and severe aplastic anemia. The following is a brief introduction to the main contents of the instructions for Eltrombopag Ethanolamine Tablets, including indications, usage and dosage, adverse reactions and precautions.

1. Indications and main uses

Eltrombopag ethanolamine tablets were initially approved to treat chronic immune thrombocytopenia (ITP) in adults and children who are unresponsive to first-line treatments (e.g., corticosteroids, immune globulin, splenectomy) to reduce the risk of bleeding. In addition, the drug is also used to treat thrombocytopenia caused by chronic hepatitis C so that patients can successfully receive interferon antiviral therapy. In recent years, eltrombopag has also been approved for the treatment of some patients with severe aplastic anemia (SAA), especially those who are refractory to immunosuppressive treatment. It can significantly increase platelet and red blood cell production.

2. Usage, dosage and medication guidance

Eltrombopag ethanolamine tablets should be used strictly in accordance with individualized doses under the guidance of a doctor. The usual starting dose for adults is 25 to 50 mg once daily, with the dose adjusted based on the patient's platelet levels. Platelet counts need to be monitored regularly during treatment to allow for dose adjustment or discontinuation. Care should be taken to avoid taking it with high-calcium foods (such as dairy products) to avoid affecting drug absorption. It is recommended to take the medicine on an empty stomach or 2 hours after a meal, and avoid supplements containing metal ions such as aluminum, calcium, iron, magnesium or selenium to avoid reducing the bioavailability of the medicine.

3. Common adverse reactions

Some patients may experience certain adverse reactions while using Eltrombopag ethanolamine tablets. Common ones include headache, fatigue, nausea, upper abdominal discomfort, elevated liver enzymes, etc. Some patients may experience thrombotic events, especially if platelet levels rise too quickly or too high. In addition, it may induce myelofibrosis or affect liver function, so it is recommended to regularly detect liver function and peripheral blood during treatment. For patients with hepatitis C, it is also important to note that drugs may aggravate liver disease, so the pros and cons need to be carefully evaluated.

4. Precautions and drug interactions

Eltrombopag is not suitable for patients with a history of active thrombosis or severe liver damage, and the risks should be fully assessed before use. During use, it is necessary to avoid taking certain metal ion preparations (such as calcium tablets and iron supplements) at the same time, as it may significantly reduce the absorption efficiency of eltrombopag. In addition, concomitant use with strong CYPenzyme inhibitors or inducers should be avoided to avoid affecting drug metabolism. Female patients should avoid becoming pregnant while taking the drug because the drug may have potential effects on the fetus. It is also recommended to suspend breastfeeding during lactation.

In general, Eltrombopag ethanolamine tablets, as a targeted platelet-promoting drug, have shown good efficacy in multiple blood diseases, especially for patients with chronic ITP and aplastic anemia. However, since this drug has certain risks on liver function, bone marrow structure and thrombosis, patients should use it under close monitoring by a doctor and have blood indicators and liver function checked regularly. Through rational drug use and individualized treatment strategies, it is possible to increase platelet levels while minimizing adverse reactions and improving patients' quality of life.

Reference materials:https://go.drugbank.com/drugs/DB06210